Key result
Chronic kidney disease patients are systematically excluded from 46-57% of recent cardiovascular disease clinical trials, resulting in a poor evidence base for treatments.
Why the study?
CKD patients are frequently excluded from CVD trials, leading to poor generalisability of assessment tools, limited safety and efficacy data, and under-treatment of CVD in this population.
Design
Review
Authors
Loading...
Limits evidence-based CVD care in CKD; leaves open whether inclusive trials would improve outcomes.
Patients with chronic kidney disease remain significantly underrepresented in cardiovascular clinical trials, limiting the evidence base for their treatment.
Warrens et al. (2022) conducted a review in Chronic Kidney Disease and Cardiovascular Disease. Chronic kidney disease patients are systematically excluded from 46-57% of recent cardiovascular disease clinical trials, resulting in a poor evidence base for treatments.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: